| Ambion Secures Growth Capital
in $10.5 Million Transaction Austin,
TX, May 1, 2003 – Ambion, Inc.
announced that it has secured financing in a
$10.5 million equity transaction. The deal was
led by Telegraph Hill Partners, L.P. In conjunction
with this financing, J. Matthew Mackowski of
Telegraph Hill Partners has joined Ambion's Board
of Directors.
Founded in Austin in 1988, Ambion has emerged
as a market leader in the field of RNA-based
life science research and molecular diagnostic
products. Researchers worldwide are exploring
the role of RNA in applications ranging from
disease therapeutics to molecular diagnostics.
"The field of RNA research is growing
rapidly and we see a tremendous opportunity to
expand our business in a number of areas including
clinical applications of RNA," said Dr.
Matt Winkler, CEO of Ambion. "This financing
will help us continue the growth of our business."
Ambion, Inc., is a market leader in the field
of RNA-based life science research and molecular
diagnostic products. Ambion maintains this leadership
role by consistently developing innovative products
for handling, preserving, isolating, detecting
and measuring RNA. These products are used for
research in areas such as molecular biology,
cell biology, microbiology, drug discovery, genomics
and molecular diagnostics.
Telegraph Hill Partners, based in San Francisco,
CA, is a private equity investment firm specializing
in life science and medical device businesses.
The firm targets investments in private companies
that demonstrate strong financial performance
and innovative products or services. Additional
information can be found at www.thpartners.net.
Ambion was advised in the transaction by Growth
Capital Partners, L.P., a leading Southwest based
merchant and investment banking firm, which is
also a shareholder of Ambion. David Sargent,
one of GCP's founders, serves on Ambion's Board
of Directors. GCP has a track record of assisting
private and public middle market companies, based
in the Southwest, with achieving their growth
objectives and maximizing shareholder value.
Ambion Press Release
Back to Top
|
